Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Clinical Trials

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Other: Placebo
Drug: VLY-686 (Tradipitant)

First Posted Date: 2016-11-22

Last Posted Date: 2024-08-06

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 152

Registration Number: NCT02970968

Locations: 🇺🇸
Vanda Investigational Site, Norfolk, Virginia, United States

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

Phase 1

Completed

Conditions: Circadian Rhythm Sleep Disorders
Non-24 Hour Sleep-Wake Disorder
Autism Spectrum Disorder
Smith-Magenis Syndrome

Interventions: Drug: tasimelteon

First Posted Date: 2016-05-18

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT02776215

Locations: 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Tradipitant
Drug: Placebo

First Posted Date: 2016-01-11

Last Posted Date: 2024-06-13

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 168

Registration Number: NCT02651714

Locations: 🇺🇸
Vanda Investigational Site, Spokane, Washington, United States

Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: tradipitant
Drug: Midazolam

First Posted Date: 2015-12-03

Last Posted Date: 2016-04-27

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT02621385

Locations: 🇨🇭
Vanda Investigational Site, Arzo, Switzerland

An Observational Study to Investigate the Effects of Rapid Transmeridian Travel

Completed

Conditions: Jet Lag Disorder

Interventions: Other: Transmeridian travel across multiple time zones

First Posted Date: 2015-09-25

Last Posted Date: 2018-06-26

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 119

Registration Number: NCT02560103

Locations: 🇺🇸
The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States
🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States